Laurus Labs share price fell 3% in the trade on Friday after the company reported weak Q1 results impacted by lower sales, operational deleverage and elevated expenses. “Performance mainly affected by operational deleverage, material drop in the CDMO business, price fall in ARV portfolio over last year,” said V V Ravi Kumar, Executive Director & Chief Financial Officer, Laurus Labs. …
Gland Pharma remains on track to deliver growth, but at the same time, it continues to be vigilant about not being over dependent on a specific geography, said brokerage Nirmal Bang in a note as it hosted the Gland Pharma management at its Annual Investor Conference to discuss the company’s business outlook. The brokerage house has a Buy rating on …
